title: Ciprofloxacin and norfloxacin for selective decontamination in patients with severe granulocytopenia.
abstract: In a randomized multicenter study, ciprofloxacin and norfloxacin, each in two different dose regimens and in combination with non-absorbable antimycotics, were administered to 51 patients with acute leukaemia undergoing aggressive remission induction chemotherapy for infection prevention. Both drugs showed an effective elimination of gram-negative potential pathogens and Staphylococcus aureus not affecting the anaerobic flora of the gastrointestinal tract. A low incidence of side effects and a satisfactory patient compliance could be observed. A daily dosage of 1,000 mg ciprofloxacin or 800 mg norfloxacin is recommended for infection prevention in severely granulocytopenic patients.
authors.affiliation: Department of Internal Medicine, Haematology and Oncology, Evangelisches Krankenhaus, Essen-Werden.
authors.forename: G
authors.initials: G
authors.lastname: Maschmeyer
authors.forename: E
authors.initials: E
authors.lastname: Haralambie
authors.forename: W
authors.initials: W
authors.lastname: Gaus
authors.forename: W
authors.initials: W
authors.lastname: Kern
authors.forename: A W
authors.initials: AW
authors.lastname: Dekker
authors.forename: H G
authors.initials: HG
authors.lastname: De Vries-Hospers
authors.forename: W
authors.initials: W
authors.lastname: Sizoo
authors.forename: W
authors.initials: W
authors.lastname: König
authors.forename: F
authors.initials: F
authors.lastname: Gutzler
authors.forename: S
authors.initials: S
authors.lastname: Daenen
mesh_terms: D000208:Acute Disease; D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001424:Bacterial Infections / Q000517:prevention & control*; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D009643:Norfloxacin / Q000008:administration & dosage / Q000627:therapeutic use*; D010865:Pilot Projects; D011897:Random Allocation; D012074:Remission Induction
chemical_list: D002939:Ciprofloxacin; D009643:Norfloxacin